1000 participants
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-08-28
- Start Date:
- 2024-10-18
- Completion:
- 2028-12-15
Conditions
- Colorectal Neoplasms
Interventions
- BIOLOGICAL
- DRUG
No Results Yet